Suboptimal control of lipid levels: Results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS)

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 5, 2016, Pages 552-553

  Chiang, Chern En ^a   Ferrières, Jean ^b   Gotcheva, Nina N ^c   Raal, Frederick J ^d   Shehab, Abdulla ^e   Sung, Jidong ^f   Henriksson, Karin M ^g,h   Hermans, Michel P ⁱ  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c NATIONAL HEART HOSPITAL   (Bulgaria)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g ASTRAZENECA R AND D   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cardiovascular disease; Hypercholesterolaemia; Lipidlowering drugs; Low density lipoprotein cholesterol; Undertreatment

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; RISK FACTOR; TREATMENT DURATION; WAIST CIRCUMFERENCE; ANALYSIS; BLOOD; CLINICAL TRIAL; HYPERCHOLESTEROLEMIA; INTERNATIONAL COOPERATION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK;

ADULT; AGED; ATORVASTATIN CALCIUM; BLOOD GLUCOSE; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INTERNATIONALITY; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK; RISK FACTORS; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84964792138     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.31179     Document Type: Article

References (43)

1. Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K and Jaarsma T: The global burden of cardiovascular disease. Eur J Cardiovasc Nurs, 2011; 10 Suppl 2: S5-S13
2. World Health Organization: The atlas of heart disease and stroke. 2004; 2014.
3. Law MR, Wald NJ and Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ, 1994; 308: 367-372
4. Law MR and Wald NJ: An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr, 1994; 48: 305-325
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr. and Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004; 110: 227-239
6. National Cholesterol Education Program: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421
7. Stone NJ, Bilek S and Rosenbaum S: Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol, 2005; 96: 53E-59E
8. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, Cooney MT, Bax J, Baumgartner H, Ceconi C, Dean V, Fagard R, Funck-Brentano C, Hasdai D, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Aboyans V, Ezquerra EA, Baigent C, Brotons C, Burell G, Ceriello A, De Sutter J, Deckers J, Del Prato S, Diener HC, Fitzsimons D, Fras Z, Hambrecht R, Jankowski P, Keil U, Kirby M, Larsen ML, Mancia G, Manolis AJ, McMurray J, Pajak A, Parkhomenko A, Rallidis L, Rigo F, Rocha E, Ruilope LM, van der Velde E, Vanuzzo D, Viigimaa M, Volpe M, Wiklund O and Wolpert C: European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012; 33: 1635-1701
9. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT and Bhatt DL: Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs, 2007; 7: 135-141
10. Law MR, Wald NJ and Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326: 1423
11. O'Regan C, Wu P, Arora P, Perri D and Mills EJ: Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med, 2008; 121: 24-33
12. Vrecer M, Turk S, Drinovec J and Mrhar A: Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther, 2003; 41: 567-577
13. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W and Payne N: A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 2007; 11: 1-160, iiiiv
14. Waters DD and Ku I: Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol, 2009; 54: 1434-1437
15. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681
16. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R and Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278
17. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, Zhang Q and Yan P: Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin, 2008; 24: 1951-1963
18. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K and Keil U: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet, 2009; 373: 929-940
19. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB and Tarasenko L: Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation, 2009; 120: 28-34
20. Gotcheva N, Raev D, Trendafilova E, Postadzhiyan A, Runev N, Vandenhoven G, Temmerman A-M and Staneva M: Assessment of lipid-lowering treatment in Bulgaria-the CEPHEUS study. Cent Eur J Med, 2013; 8: 627-637
21. Arafah M, Al-Hinai AT, Mahmeed WA, Al-Rasadi K, Tamimi OA, Herz SA, Anazi FA, Nemer KA, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Jassim OA, Hallaq OA, Baslaib FO, Alawadhi M, Amin H, Al-Hashmi K and Shehab A: Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. Angiology, 2014; 65: 919-926
22. Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, Michel G and Sansoy V: Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin, 2010; 26: 445-454
23. Park JE, Chiang CE, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, Khoo KL and Chan HW: Lipidlowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol, 2012; 19: 781-794
24. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M, Hussain R, Cassim F, Nortje M, Vandehoven G and Temmerman AM: CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr, 2011; 22: 234-240
25. Hammoudeh AJ, Echtay A, Ghanem GY and Haddad J: Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Curr Med Res Opin, 2014; 30: 1957-1965
26. Sukonthasarn A, Homsanit M, Prommete B, Chotinaiwattarakul C, Piamsomboon C and Likittanasombat K: Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey. J Med Assoc Thai, 2011; 94: 1424-1434
27. Elisaf MS and Nikas N: Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS Greece survey. Angiology, 2010; 61: 465-474
28. Ferrières J, Gousse ET, Fabry C and Hermans MP: Assessment of lipid-lowering treatment in France-the CEPHEUS study. Arch Cardiovasc Dis, 2008; 101: 557-563
29. International Conference on Harmonisation: Guidelines for good clinical practice. 1996; 2014: PDF available online: http://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline. pdf
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H and Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847
31. Teramoto T, Kashiwagi A, Mabuchi H and Investigators JL: Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res Clin Exp, 2005; 66: 80-95
32. Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M and Kishiwada Atherosclerosis Prevention Study G: Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin. Cardiovasc Ther, 2014; 32: 97-104
33. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr., Watson K and Wilson PW: 2013 ACC/ AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol, 2014; 63: 2889-2934
34. Liberopoulos EN, Florentin M, Mikhailidis DP and Elisaf MS: Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf, 2008; 7: 717-725
35. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M and Davidson MH: Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J, 2006; 152: 976-981
36. Zhang R, Zhao L, Liang L, Xie G and Wu Y: Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy. Lipids Health Dis, 2012; 11: 59
37. Hammond G, Mochari-Greenberger H, Liao M and Mosca L: Effect of gender, caregiver, on cholesterol control and statin use for secondary prevention among hospitalized patients with coronary heart disease. Am J Cardiol, 2012; 110: 1613-1618
38. Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Ferrieres J, Verdejo J and Chiang CW: Low-and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J, 2009; 158: 860-866
39. Victor BM, Teal V, Ahedor L and Karalis DG: Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol, 2014; 113: 1611-1615
40. Charland SL, Agatep BC, Herrera V, Schrader B, Frueh FW, Ryvkin M, Shabbeer J, Devlin JJ, Superko HR and Stanek EJ: Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J, 2014; 14: 272-280
41. Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS and Voora D: Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med, 2014; 4: 147-162
42. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA and Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol, 2003; 92: 152-160
43. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, Goudevenos J, Mikhailidis DP and Elisaf MS: Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin, 2006; 22: 1123-1131